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A Stimulatory Role for cGMP-Dependent
Protein Kinase in Platelet Activation
brand disease in which a genetic deficiency in GPIb-IX
or vWF, respectively, causes defects in platelet adhe-
sion and activation and results in bleeding disord-
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Biedersteiner Straße 29 portant secondary messenger synthesized by guanylyl
80802 Munchen cyclases. Elevation of intracellular cGMP activates
3 Medizinische Uniklinik Bau 4 cGMP-dependent protein kinase (PKG) (Haslam et al.,
Klinische Biochemie 1999). PKG regulates the functions of several intracellu-
97080 Wuerzburg lar molecules and pathways including the vasodilator-
Germany stimulated phosphoprotein (VASP) (Halbrugge et al.,
1990) and extracellular stimuli-responsive kinase (ERK)
pathway (Hood and Granger, 1998; Li et al., 2001). One
important finding in cGMP signaling is that cGMP medi-Summary
ates nitric oxide (NO)-induced vascular smooth muscle
relaxation (Furchgott and Vanhoutte, 1989). Based onIt is currently accepted that cGMP-dependent protein
this mechanism, a specific cGMP-enhancing agent, sil-kinase (PKG) inhibits platelet activation. Here, we
denafil (VIAGRA), has been developed and used to treatshow that PKG plays an important stimulatory role in
erectile dysfunction. Sildenafil selectively inhibits phos-platelet activation. Expression of recombinant PKG in
phodiesterase 5 (PDE5) that hydrolyzes cGMP and thusa reconstituted cell model enhanced von Willebrand
factor (vWF)-induced activation of the platelet integrin enhances intracellular cGMP levels (Corbin and Francis,
IIb3. PKG knockout mice showed impaired platelet 1999). The role of the cGMP-PKG pathway in platelet
responses to vWF or low doses of thrombin and pro- activation was controversial since increases in platelet
longed bleeding time. Human platelet aggregation in- cGMP levels were observed in response to both plate-
duced by vWF or low-dose thrombin was inhibited by let agonists (thrombin, ADP, or collagen) and inhibitors
PKG inhibitors but enhanced by cGMP. Furthermore, (NO donors such as sodium nitroprusside) (for review,
a cGMP-enhancing agent, sildenafil, promoted vWF- see Haslam et al., 1999). It is currently accepted that
or thrombin-induced platelet aggregation. The cGMP- PKG inhibits platelet activation (Haslam et al., 1999).
stimulated platelet responses are biphasic, consisting This concept is supported by the finding that preincuba-
of an initial transient stimulatory response that pro- tion of cGMP analogs with platelets inhibits platelet acti-
motes platelet aggregation and a subsequent inhibi- vation (Massberg et al., 1999; Mellion et al., 1981). Con-
tory response that limits the size of thrombi. sistent with this concept, nitric oxide (NO) donors that
inhibit platelet activation enhance intracellular cGMP
Platelet adhesion and activation are critical to the devel- (Haslam et al., 1999). This concept, however, does not
opment of thrombotic diseases such as heart attack explain why physiological platelet activators elevate
and stroke (Ginsberg et al., 1992; Shattil et al., 1998). platelet cGMP levels. Also, sildenafil enhances intracel-
Under flow conditions seen in stenotic arteries, the initial lular cGMP, but does not significantly inhibit platelet
platelet adhesion and activation require the interaction activation (Wallis et al., 1999). On the other hand, a small
between subendothelial bound von Willebrand factor number of patients taking sildenafil have developed un-
(vWF) and an important platelet adhesion receptor, the explained thrombotic conditions including heart attack
glycoprotein Ib-IX complex (GPIb-IX) (Du and Ginsberg, (Arora et al., 1999; Feenstra et al., 1998; Mitka, 2000;
1999; Sakariassen et al., 1979; Savage et al., 1996; Weiss Porter et al., 1999).
et al., 1978). GPIb-IX interaction with vWF initiates plate- In this study, we present the novel finding that the
let adhesion and triggers activation of the platelet integ- cGMP-PKG pathway plays an important stimulatory role
rin IIb3, leading to integrin-dependent stable platelet in GPIb-IX-mediated platelet activation and propose a
adhesion, spreading and aggregation (De Marco et al., new concept that cGMP-induced platelet responses are
1985; Gralnick et al., 1985; Gu et al., 1999; Savage et biphasic, consisting of an early stimulatory response
al., 1996, 1992). The importance of GPIb-IX and vWF in that promotes platelet activation followed by a delayed
thrombosis and hemostasis is manifested in the inher-
platelet inhibition that serves to limit the size of platelet
ited diseases Bernard-Soulier syndrome and von Wille-
aggregates. Our findings explain previous controversies
and provide revisions to the current concept of cGMP
signaling in platelet activation.*Correspondence: xdu@uic.edu
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Results
PKG Promotes GPIb-IX-Mediated Integrin
Activation in a Reconstituted Integrin
Activation Model
We have recently shown that activation of the platelet
integrin IIb3 can be reconstituted in Chinese hamster
ovary (CHO) cells expressing both recombinant human
GPIb-IX and integrin IIb3 (123 cells) (Gu et al., 1999).
In this model, binding of vWF to GPIb-IX triggers activa-
tion of integrin IIb3, allowing specific binding of fibrino-
gen (a physiological ligand of integrin IIb3). We found
in preliminary studies that a PKG inhibitor, KT5823, in-
hibited GPIb-IX-mediated integrin activation in this sys-
tem (data not shown). To specifically identify the roles
of PKG in GPIb-IX-mediated integrin activation, cDNAs
encoding human PKG I or PKG I were transfected
into 123 cells. Results obtained with PKG I (Figure 1)
and PKG I (data not shown) were similar. Immunoblot-
ting and PKG activity assays confirmed that human PKG
I was expressed (Figure 1A). Three different clones each
of PKG I- or I-expressing cells were examined for
vWF-induced integrin activation, as indicated by spe-
cific binding of soluble fibrinogen. We found that a low
concentration of vWF (12 g/ml) induced a slight in-
crease in fibrinogen binding to vector-transfected 123
cells. In contrast, all tested 123 cell lines expressing
human PKG showed a significantly enhanced fibrinogen
binding (Figures 1B and 1C). More importantly, vWF-
induced fibrinogen binding was dramatically increased
in PKG-transfected cells in the presence of a membrane-
permeable PKG activator, 8-bromo-cGMP (Figures 1B
and 1C). Thus, recombinant human PKG stimulates
GPIb-IX-mediated integrin activation in the reconstitu-
ted CHO cell model.
GPIb-IX-mediated integrin activation is important in
stable platelet adhesion to immobilized vWF. Thus, we
examined if PKG could augment this process. CHO cells
Figure 1. Expression of Recombinant PKG Promotes GPIb-IX-expressing comparable levels of recombinant human
Mediated Integrin ActivationGPIb-IX and/or integrin IIb3 (Gu et al., 1999) were per-
(A) CHO cells expressing GPIb-IX and integrin IIb3 (123 cells) werefused into vWF-coated capillary tubes. GPIb-IX-
transfected with cDNA encoding PKGI or vector. Expression ofexpressing cells (1b9 cells) displayed transient adhesion
PKG I in 123 cells was detected by immunoblotting with an anti-and rolling on the vWF surface but failed to stably adhere
human PKG I antibody (Insert), and recombinant PKG activity was
(Figure 2A). Cells expressing integrin IIb3 alone (2b3a determined in the absence or presence of 20 M 8-bromo-cGMP
cells) also showed minimal adhesion to vWF. 123 cells as previously described (Colbran et al., 1992). Results are expressed
that express both GPIb-IX and integrin IIb3 adhered to as mean  SD (n  3).
(B and C) The reconstitution of GPIb-IX-mediated integrin activationvWF as expected (Figure 2A). Remarkably, PKG-trans-
in CHO cells has been described previously (Gu et al., 1999). PKG-fected 123 cells showed an enhanced stable cell adhe-
or vector-transfected 123 cells were incubated with Oregon green-sion compared to 123 cells (Figure 2A). Stable adhesion
labeled fibrinogen (Fg) (30 g/ml) and 1 mg/ml ristocetin (no cGMP)of PKG-expressing cells was inhibited by RGDS peptide
for 30 min with (vWF) or without (no vWF) the addition of 12 g/
(an integrin inhibitor), but not by the same concentra- ml of vWF. These cells were also incubated with Oregon green-
tion of control RGES peptide, indicating that PKG-stimu- labeled Fg, ristocetin, and 0.1 mM 8-bromo-cGMP (cGMP) with
lated stable adhesion is integrin dependent (Figure 2B). or without the addition of vWF. Nonspecific binding was estimated
by adding RGDS (Fg RGDS). Cells were analyzed by flow cytome-Furthermore, integrin-dependent adhesion of PKG-
try. Quantitative results from three experiments are expressed asexpressing 123 cells to vWF was enhanced by a specific
fibrinogen binding index (total bound fluorescence [Fg]/nonspecifi-cGMP-enhancing drug, sildenafil, or by 8-bromo-cGMP
cally bound fluorescence [Fg  RGDS]) and shown in (B) (mean (data not shown). These data demonstrate that PKG
SD). Results from a representative experiment are shown in (C).
promotes GPIb-IX- and integrin-dependent cell adhe-
sion to vWF.
vWF. Thus, if PKG plays a role in GPIb-IX-mediated
integrin activation, deletion of the PKG gene should re-GPIb-IX- and Integrin-Dependent Platelet Spreading
sult in decreased platelet spreading on vWF. To specifi-on vWF Is Inhibited in PKG Knockout Mice
cally determine the physiological role of PKG in GPIb-A physiological role for GPIb-IX-mediated integrin acti-
vation is to mediate platelet spreading on immobilized IX-mediated integrin activation, platelets from wild-type
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Figure 2. PKG Enhances GPIb-IX and Integrin-Dependent Cell Ad-
hesion under Flow
(A) Stable adhesion of CHO cells expressing recombinant GPIb-IX
alone (1b9); integrin IIb3 alone (2b3a); both GPIb-IX and integrin
IIb3 (123); or expressing GPIb-IX, integrin IIb3, and PKG I
(123PKG) under flow was performed as described in Experimental
Procedures. Adherent cells at 15 randomly selected locations in a
vWF-coated capillary tube were counted. A significantly increased
stable adhesion of 123PKG cells compared to 123 cells was ob-
served (p  0.001).
(B). Vector transfected 123 cells or 123PKG cells were perfused into
vWF-coated capillary tubes either alone or in the presence of an
integrin inhibitor RGDS peptide (4 mM) (RGDS), or a control pep-
tide, RGES (4 mM) (RGES). Stable adhesion of 123PKG cells was
significantly higher than vector-transfected 123 cells (p  0.001)
and was inhibited by RGDS peptide (p  0.001), but not RGES
peptide (p  0.713).
or PKG knockout mice (Massberg et al., 1999; Pfeifer
et al., 1998; Wegener et al., 2002) were allowed to adhere
and spread on immobilized vWF stained with phalloidin
and examined by fluorescence microscopy. As ex-
pected, wild-type mouse platelets fully spread on vWF
(Figure 3A; WT). Spreading of wild-type platelets was
integrin dependent since it was blocked by the integrin
inhibitor, RGDS (Figure 3A, RGDS). In contrast to wild-
type mice, platelets from PKG knockout mice spread
poorly on vWF, in a manner similar to RGDS-treated
Figure 3. Inhibition of Platelet Spreading on vWF in PKG Knockoutplatelets (Figure 3A, KO). Consistent with the results
Mice and in PKG Inhibitor-Treated Mouse and Human Platelets
obtained with PKG knockout platelets, treatment of wild-
(A) Washed platelets from wild-type mice (WT) or homozygous PKG
type platelets with the PKG inhibitor, Rp-pCPT-cGMP, knockout mice (KO) were allowed to adhere and spread on immobi-
also inhibited platelet spreading on vWF (Figure 3A, lized vWF at 37C for 1 hr as described in Experimental Procedures.
WTRp-pCPT-cGMP). These results indicate that PKG Wild-type mouse platelets were also allowed to adhere to immobi-
lized vWF in the presence of integrin inhibitor RGDS peptide (RGDS)plays an important role in GPIb-IX-mediated platelet ac-
(4 mM) or PKG inhibitor Rp-pCPT-cGMP (0.25 mM).tivation and integrin-dependent platelet spreading on
(B) Washed human platelets were treated without (control) or withvWF. These results also indicate that the PKG inhibitor
integrin inhibitor RGDS or PKG inhibitor Rp-pCPT-cGMP and al-
Rp-pCPT-cGMP specifically inhibited PKG function in lowed to adhere and spread on immobilized vWF. Adherent platelets
platelets, equivalent to the results obtained with PKG were stained with Rhodamine-labeled phalloidin and examined un-
knockout mice. der a Nikon inverted fluorescence microscope (60	 objective lens).
PKG Promotes vWF-Induced Human
Platelet Activation by the PKG inhibitor, Rp-pCPT-cGMP (Figure 3B), indi-
cating that PKG is important in integrin-dependent hu-The above studies establish that PKG promotes GPIb-
IX-dependent integrin activation in a reconstituted in- man platelet spreading on vWF.
In humans, vWF binding to GPIb-IX not only inducestegrin activation model in CHO cells and in mouse plate-
lets. It has recently been shown that vWF induces much integrin-dependent platelet spreading on vWF, but also
induces fibrinogen binding to integrin IIb3 and integrin-more robust GPIb-IX-dependent platelet activation in
humans than in mice (Canobbio et al., 2001). Thus, we dependent platelet aggregation. We therefore examined
the effects of PKG inhibitors or stimulators on vWF-examined whether PKG is important in GPIb-IX-depen-
dent integrin activation in human platelets. Figure 3B induced fibrinogen binding to integrin IIb3 and platelet
aggregation. GPIb-IX on platelets does not normallyshows that spreading of human platelets on vWF was
integrin dependent because it was inhibited by RGDS. bind soluble vWF, but it does bind to subendothelial-
bound vWF at sites of vascular injury. In in vitro studies,Spreading of human platelets on vWF was also inhibited
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the vWF modulators ristocetin or botrocetin mimic the
effects of subendothelial matrix to induce vWF binding
to human GPIb-IX. At appropriate concentrations, risto-
cetin-induced vWF binding to GPIb-IX causes reversible
agglutination of platelets and activation of integrin IIb3,
leading to a second wave of platelet aggregation (Fig-
ures 4A and 4B). We found that the inhibitors of PKG,
Rp-pCPT-cGMP and KT5823, diminished the integrin-
dependent second wave of platelet aggregation (Figures
4A and 4B) and fibrinogen binding to platelets (Figure 4E)
induced by vWF and ristocetin. Furthermore, 8-bromo-
cGMP or 8-dibutyl-cGMP, when added to platelets to-
gether with a subthreshold concentration of ristocetin,
induced integrin-dependent platelet aggregation (Fig-
ures 4C and 4D). Thus, we conclude that PKG plays an
important stimulatory role in GPIb-IX-dependent human
platelet activation.
vWF Induces an Increase in Platelet cGMP Levels
PKG activity is regulated by cGMP levels. Thus, if PKG
is activated downstream of GPIb-IX, ligand binding to
GPIb-IX would be expected to stimulate an increase in
intracellular cGMP levels. Indeed, vWF induced a dra-
matic increase in platelet cGMP. The vWF-induced in-
crease in cGMP levels was inhibited by a blocking anti-
GPIb monoclonal antibody, AK2, but not control IgG
(Figure 4F). The cGMP levels in vWF-stimulated platelets
were comparable to those in platelets stimulated with
glyco-SNAP1 (a compound that releases nitric oxide
and thus activates PKG) (Figure 4F). Thus, ligand binding
to GPIb-IX increases the intracellular cGMP level to an
extent that is capable of activating PKG.
Figure 4. Effects of PKG Inhibitors and Activators on Integrin-
The Role of PKG in Low-Dose Thrombin-InducedDependent Human Platelet Aggregation Induced by vWF-GPIb-IX
Interaction Platelet Aggregation
In addition to binding vWF, GPIb-IX also facilitates low-(A) Platelet rich-plasma (PRP) from a healthy human donor was
preincubated at 37C for 5 min with PKG inhibitors KT5823 (2 M) dose thrombin-induced platelet aggregation (Greco et
or Rp-pCPT-cGMP (0.25 mM). PRP was also incubated with DMSO al., 1996; Jamieson and Okumura, 1978; Yamamoto et
(vehicle for KT5823), the PKA inhibitor KT5720 (2 M), or buffer al., 1985). To study the role of PKG in low-dose thrombin-
(control). The vWF modulator, ristocetin, was then added to induce
induced platelet activation, 0.05 units/ml of -thrombinvWF-GPIb-IX interaction. Ristocetin-induced platelet aggregation
was used to induce human platelet aggregation, whichwas recorded using a platelet aggregometer.
(B) Quantitative data (mean  SD) from three experiments as de- was integrin- and GPIb-IX-dependent as indicated by
scribed in (A). the inhibitory effects of RGDS and a monoclonal anti-
(C) A subthreshold concentration of ristocetin was added to PRP body specific for the thrombin binding site of GPIb
immediately followed by addition of 8-bromo-cGMP or buffer (con- (Ruan et al., 1987; Ward et al., 1996) (Figure 5A). Platelet
trol) to induce platelet aggregation. PRP was also preincubated with
aggregation was inhibited by the PKG inhibitors KT5823the integrin inhibitor RGDS before adding ristocetin and 8-bromo-
(2 M) and Rp-pCPT-cGMP (Figures 5A and 5B). On thecGMP (8-bromo-cGMP  RGDS).
(D) A subthreshold concentration of ristocetin (1 mg/ml) was added other hand, the membrane-permeable cGMP analog,
to PRP immediately followed by addition of buffer (control), 8-bromo-cGMP, induced platelet aggregation when
8-bromo-cGMP (100 M,) or 8-dibutyl-cGMP (100 M) to induce added to platelets together with a subthreshold concen-
platelet aggregation. The data represent the mean SD of percent- tration (0.02 units/ml) of thrombin (Figure 5C).
age of aggregation (light transmission) from three experiments.
To further examine the roles of PKG in low-dose(E) Washed platelets were preincubated without or with 0.25 mM
PKG inhibitor, Rp-pCPT-cGMP (vWF  Rp), at 22C for 10 min.
The platelets were then allowed to bind Oregon green 488-labeled
fibrinogen (30 g/ml) in the absence (control) or presence of 20
(F) Washed platelets (3 	 108/ml) were preincubated at 37C for 10g/ml vWF and 1 mg/ml ristocetin (vWF) or in the presence of risto-
cetin alone as an additional control. Fibrinogen binding was exam- min with buffer, control IgG, or a blocking monoclonal antibody
against GPIb, AK2. The platelets were then further incubated in ained by flow cytometry. Nonspecific binding of fibrinogen was esti-
mated by adding a saturating concentration of integrin inhibitor, platelet aggregometer for 5 min after addition of buffer (control), 1.0
mg/ml ristocetin only (Risto), ristocetin plus 15 g/ml vWF (vWF),RGDS peptide (1 mM). The fibrinogen binding index is the ratio
between mean fluorescence intensity in the absence of RGDS and or glyco-SNAP1 (100 M). The reaction was stopped by addition of
400 l of ice-cold 12% (w/v) trichloroacetic acid. cGMP concentra-the mean fluorescence intensity in the presence of RGDS peptide.
The fibrinogen binding index is one when there is no specific fibrino- tions were determined using a cGMP enzyme immunoassay kit.
Results are expressed as mean  SD (n  3).gen binding.
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Figure 5. Effects of PKG Inhibitors and Stimulators and Effect of
the PKG Knockout on Thrombin-Induced Platelet Aggregation
(A) Washed platelets were preincubated with 40 g/ml anti-GPIb
monoclonal antibody SZ2, integrin inhibitor RGDS, or PKG inhibitors
KT5823 (2 M) or Rp-pCPT-cGMP (0.25 mM) for 5 min. The platelets
were also preincubated with DMSO (vehicle for KT5823), KT5720,
or buffer (control) as controls. -thrombin (0.05 units/ml) was then
Figure 6. Effects of Sildenafil on Human Platelet Aggregation andadded to induce platelet aggregation. Nonspecific IgG and RGES
Effect of the PKG Knockout on In Vivo Bleeding Time in Micepeptide were also examined as additional controls but had no effect
(A) Increasing concentrations of sildenafil or control 0.15 M NaCl(data not shown).
solution were added to human PRP followed by a subthreshold(B) Experiments described in (A) were repeated three times with the
concentration of ristocetin. Platelet aggregation was recorded usingresults quantified as percentage of light transmission (mean  SD).
a platelet aggregometer.(C) A subthreshold dose of thrombin was added to human platelets
(B) Washed human platelets were preincubated in the absence orfollowed immediately by addition of the PKG activator, 8-bromo-
presence of a PKG inhibitor, Rp-pCPT-cGMP. Sildenafil or controlcGMP, or buffer (control). Shown in the figure are representative
buffer was then added to the platelets followed by addition of sub-results of at least three experiments.
threshold doses of thrombin to induce platelet aggregation.(D) Washed platelets from wild-type (WT) or PKG
/
 mice (KO) in
(C) Experiments described in (B) were repeated three times with themodified Tyrode’s solution (Du et al., 1991) were stimulated with
results quantified as percentage of light transmission.0.025 u/ml of -thrombin in a turbidometric platelet aggregomoter.
(D) Bleeding time tests were performed blind to genotype in lit-Wild-type platelets were also preincubated with the PKG inhibitor
termate mice (5–6 weeks old) generated from mating PKG/
 mice,Rp-pCPT-cGMP (0.25 mM) for 5 min and then exposed to 0.025/ml
using methods described under Experimental Procedures. Geno--thrombin.
types of the tested mice were subsequently determined by PCR(E) A subthreshold dose of thrombin was added to wild-type (WT)
analysis. The solid triangles represent the bleeding time of a singleor PKG
/
 (KO) mouse platelets followed immediately by addition
mouse. The bar represents the median bleeding time of the group.of the PKG activator 8-bromo-cGMP (10 M) or buffer (control).
Note that although the variance of bleeding time was broad in both
the control and PKG
/
 groups (reflecting that multiple factors may
influence the outcome of this in vivo test), the difference betweenthrombin-induced platelet activation, a low dose of
PKG/ and PKG
/
 mice is statistically significant (p  0.017).-thrombin was added to platelets from wild-type or
PKG knockout mice to induce aggregation. We found
that platelet aggregation was markedly reduced in PKG
knockout mice compared to wild-type mice (Figure 5D). The cGMP-Enhancing Drug Sildenafil Promotes
Platelet Activation In VitroWild-type platelets treated with the PKG inhibitor Rp-
pCPT-cGMP also showed reduced platelet aggregation The cGMP-enhancing drug sildenafil increases intracel-
lular cGMP and activates PKG. Thus, if PKG stimulatessimilar to PKG knockout mice (Figure 5D). As previously
reported (Massberg et al., 1999), collagen-induced platelet activation, sildenafil might also be stimulatory.
Indeed, addition of sildenafil to platelets together withplatelet aggregation was normal in PKG knockout mice
or PKG inhibitor-treated wild-type mice (data not subthreshold concentrations of either ristocetin (Figure
6A) or thrombin (Figures 6B and 6C) induced plateletshown), suggesting that PKG promotes platelet aggre-
gation in an agonist-selective manner. Furthermore, ad- aggregation. The stimulatory role of sildenafil was PKG
dependent since it was inhibited by preincubation ofdition of a membrane-permeable cGMP analog, 8-bromo-
cGMP, enhanced platelet aggregation induced by a platelets with the PKG inhibitor Rp-pCPT-cGMP. Since
sildenafil functions by specifically increasing endoge-subthreshold concentration of thrombin in wild-type
platelets, but not in PKG knockout platelets (Figure 5E). nous cGMP, this result further excludes the possibility
of nonspecific effects of exogenous cGMP analogs andThese data indicate that PKG promotes platelet activa-
tion induced by low doses of thrombin. supports the conclusion that the cGMP-PKG pathway
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promotes platelet activation. This result also provides
novel in vitro evidence that sildenafil may potentiate
platelet activation.
Prolonged Bleeding Time in PKG Knockout Mice
The above ex vivo data show that PKG promotes platelet
activation. To investigate if the stimulatory role of PKG
is important for hemostasis in vivo, tail bleeding time
tests were performed blind to genotype in 5- to 6-week-
old avertin-anesthetized littermates generated from het-
erozygous breeding of PKG/
mice. Genotypes of these
mice were subsequently determined by PCR analyses,
using DNA extracted from the amputated tail after the
bleeding time tests. Among the 158 mice tested, 38 were
PKG/ mice (wild-type) with a median bleeding time of
67.5 s, and 104 were PKG/
 mice with a median bleed-
ing time of 85.0 s. In contrast, the median bleeding time
of 16 PKG
/
 mice (286.0 s) was significantly prolonged
(p  0.017) (Figure 6D). Thus, PKG plays an important
role in supporting hemostasis in vivo.
cGMP Induces Biphasic Platelet Responses
The stimulatory role of the cGMP pathway in GPIb-IX-
Figure 7. Biphasic Roles of cGMP in Platelet Activationdependent platelet activation appears to contradict the
concept that cGMP inhibits platelet activation. However, (A) Washed platelets were preincubated without (control) or with
8-pCPT-cGMP (50, 100, and 500 M) for 0, 5, and 10 min and thenwe noted that there is a major difference in the timing
exposed to thrombin to examine the inhibitory effects of cGMP onof cGMP elevation between our experiments and those
platelet aggregation. At the zero time point, cGMP had no inhibitoryin previous studies. We therefore examined the relation-
effect but promoted platelet aggregation induced by subthreshold
ship between the timing of cGMP elevation and its ef- concentrations of thrombin (cf. Figure 5). After prolonged incubation,
fects on platelets. Addition of cGMP analogs (0.05–0.5 cGMP became inhibitory.
mM) simultaneously with platelet agonists (ristocetin (B) Washed platelets (1 	 109/ml) were incubated with 8-bromo-
cGMP for increasing lengths of time and then solublized directly[Figure 4C] or thrombin [Figure 5B]) had no inhibitory
into SDS-PAGE sample buffer. Phosphorylation of VASP was de-effects but promoted platelet aggregation (also see Fig-
tected by immunoblotting with the monoclonal antibody 16C2,ure 7A). However, when platelets were preincubated
which specifically recognizes phosphorylated Ser239 in VASP (Smo-with cGMP for increasing lengths of time, the stimulatory
lenski et al., 1998). Phosphorylation of ERK MAP kinase was de-
effect was diminished, and cGMP became increasingly tected by immunoblotting, using a rabbit antibody specific for the
inhibitory (Figure 7A). With increasing cGMP concentra- phosphorylated Thr202/Tyr204 site of ERK. Data shown are representa-
tions, the inhibitory phase appeared progressively ear- tive of three independent experiments.
(C) Upon vascular injury, platelets adhere to the subendothelial ma-lier. Only at unusually high 8-pCPT-cGMP concentra-
trix via GPIb-IX interaction with vWF and are exposed to solubletions (1 mM) were the inhibitory effects seen without
agonists such as thrombin. This induces cGMP elevation, whichpreincubation (data not shown). Thus, cGMP exerts a
synergizes with G protein-coupled signaling pathways, leading totime- and concentration-dependent biphasic effect on
platelet activation and formation of a hemostatic thrombus. Contin-
platelet activation. Consistent with the delayed inhibi- ued cGMP elevation in aggregated platelets induces a second phase
tory effects of cGMP on platelet aggregation, we also of inhibitory cGMP signaling, resulting in inhibition of further recruit-
observed that the cGMP-induced phosphorylation of ment of platelets. This prevents the overgrowth of hemostatic throm-
bus (Freedman et al., 1997), thus reducing the probability of throm-VASP (a protein important in the inhibitory effects of
bosis during normal hemostasis. However, in patients at thromboticcGMP [Aszodi et al., 1999; Hauser et al., 1999]) is also
risk, the initial phase of cGMP-promoted thrombus formation maydelayed with significant phosphorylation occurring only
be sufficient to cause thrombosis.after a 10 min incubation with cGMP (Figure 7B). In
contrast to VASP phosphorylation, a different cGMP-
induced intracellular event, the cGMP-induced phos-
important stimulatory role in GPIb-IX-dependent plateletphorylation of ERK (a protein kinase important in stim-
activation induced by vWF and thrombin; and second,ulating platelet activation) (Li et al., 2001), occurred
that platelet responses to cGMP are biphasic, consistingrapidly, reaching a maximum within 1 min of cGMP incu-
of an early stimulatory response that promotes throm-bation. It was, however, rapidly dephosphorylated with
bus formation and a late inhibitory response that limitsincreasing length of cGMP incubation (Figure 7B). These
the size of platelet aggregates. A direct pharmacologicaldata indicate that the apparently paradoxical effects of
implication derived from these concepts and data iscGMP in platelets are in fact biphasic effects: an early
that cGMP-enhancing drugs, such as sildenafil, maystimulatory effect and a delayed inhibitory effect.
promote platelet activation in the presence of sub-
threshold concentrations of the platelet agonists, throm-Discussion
bin, and vWF.
The conclusion that GPIb-IX mediates platelet activa-Two novel concepts are derived from the data presented
in this paper: first, that the cGMP-PKG pathway plays an tion via the PKG pathway is based on data derived from
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experiments using platelets from PKG knockout mice, tion than for high concentrations of NO donors (Azula
pharmacological studies in human platelets, and studies et al., 1996; Maurice and Haslam, 1990), suggesting that
using recombinant PKG expression in a reconstituted the inhibitory effects of NO donors may involve either a
integrin activation model. The results obtained using higher peak of cGMP elevation or other pathways in
recombinant DNA techniques and PKG knockout mice addition to cGMP (Azula et al., 1996; Maurice and Has-
exclude the possibility of nonspecific effects of pharma- lam, 1990; Yan and Smith, 2000). Interestingly, it was
cological reagents, and studies in human platelets indi- reported that cGMP elevation induced by endogenous
cate that the results obtained in the CHO cell model and platelet NO had no inhibitory effect on primary platelet
knockout mouse model appropriately reflect the events activation but, after a delay, inhibited recruitment of
that occur in human platelets. Furthermore, the effects subsequently added platelets to already formed aggre-
of PKG inhibitors and activators as well as cGMP- gates (Freedman et al., 1997). It was also shown that
enhancing agents with different mechanisms of action while platelet adhesion and thrombus formation oc-
are consistent with each other and with the experiments curred normally at a site of ischemia/reperfusion injury
using recombinant DNA technologies, making it unlikely (involving multiple platelet agonists) in wild-type mice,
that potential nonspecific effects of one drug could influ- more platelets appeared to be recruited to the site
ence the outcome of our studies. GPIb-IX, as a receptor of ischemia/reperfusion injury in PKG-deficient mice
for vWF, plays critical roles in platelet adhesion and (Massberg et al., 1999), Thus, the biphasic response of
activation. Although it is known that vWF binding to platelets to cGMP elevation may be of physiological
GPIb-IX activates platelets, the signaling pathways re- significance because this response would not only me-
main poorly defined. Thus, our finding of a PKG-depen- diate rapid activation of platelets upon vascular injury
dent platelet activation pathway is significant not only and formation of a primary hemostatic thrombus, but
because it provides convincing evidence of a stimula- would also serve to inhibit the overgrowth of thrombus
tory role for PKG in platelet activation, but also because to prevent the occlusion of blood vessels during normal
it defines a novel signaling mechanism of platelet adhe- hemostasis (Figure 7C). The mechanisms for the bipha-
sion and activation. sic effect of cGMP remain to be investigated. Our data
An important platelet agonist, thrombin, requires suggest that cGMP induces an early activation of the
PARs to induce platelet activation. However, at low ERK pathway that is important in platelet activation (Li et
thrombin concentrations, PARs are not sufficient, and al., 2001), followed by a delayed VASP phosphorylation,
a different thrombin receptor, GPIb-IX, is also required. which is involved in platelet inhibition (Figure 7B). We
At present, it is not clear how GPIb-IX is involved in have also found that cAMP-dependent protein kinase
thrombin-induced platelet activation. One hypothesis is is important in cGMP-induced VASP phosphorylation
that GPIb-IX functions as a thrombin-presenting recep- and platelet inhibition (Z. Li et al., submitted). Thus,
tor that enhances the interaction between PARs and one of the possible mechanisms for the transition from
thrombin (Coughlin, 2000). Alternatively, it is hypothe- stimulatory to inhibitory responses may involve the
sized that GPIb-IX may transmit signals that synergize crosstalk between the cGMP and cAMP pathways.
with PARs in promoting platelet activation (Greco et Our finding of a stimulatory role of the cGMP-PKG
al., 1996). Our data suggest a possible PKG-dependent pathway in platelet activation is important not only to
signaling mechanism for the synergism between GPIb- the understanding of platelet physiology, but also to the
IX and PARs. It is important to note that the stimulatory pharmacology and therapeutic applications of cGMP-
role of cGMP manifests only when platelets are exposed enhancing drugs such as sildenafil. Our data suggest
simultaneously to the agonists, -thrombin, or vWF. Ele- that although sildenafil by itself is not sufficient to cause
vation of cGMP alone is not sufficient to activate plate- platelet aggregation, this drug enhances platelet activa-
lets (data not shown). Thus, it appears that the cGMP- tion in the presence of subthreshold concentrations of
PKG pathway is not the only pathway required for
thrombin or vWF, agonists that are likely to be present
GPIb-IX-mediated integrin activation. In this respect, it
at sites of vascular injury or atherosclerotic lesions. Fur-
has been shown that vWF-induced platelet activation
thermore, the half maximal effective concentration ofinvolves the coordination of different signaling pathways
sildenafil that promotes vWF-induced platelet activationand requires the Fc receptor IIa/Fc receptor -chain
is0.1 M. In comparison, the mean peak plasma con-and Syk signaling pathway (Canobbio et al., 2001; Sul-
centration of sildenafil in healthy males after oral admin-lam et al., 1998; Wu et al., 2001).
istration of a 100 mg tablet is0.66M (http://www.pfizer.Although a stimulatory role for the cGMP-PKG path-
com/hml/pi’s/viagrapi.pdf). Thus, sildenafil may possi-way in platelet activation apparently contradicts previ-
bly potentiate platelet activation in patients with preex-ous observations of inhibitory effects of cGMP analogs
isting thrombotic conditions. Further clinical studiesor NO donors on platelet activation, this contradiction
may help to determine if this effect of sildenafil couldis well explained by our finding that cGMP induces bi-
explain the thrombotic complications in a small numberphasic platelet responses. That is, the early stimulatory
of patients taking sildenafil.response to cGMP is followed by an inhibitory response
(Figure 7). Consistent with our finding, inhibitory effects
Experimental Proceduresof cGMP reported in previous publications were ob-
served only after prolonged preincubation of cGMP ana-
Effects of Recombinant PKG Expression on GPIb-IX-
logs with platelets. The lower the cGMP concentration, Mediated Integrin Activation
the longer the required preincubation time (Massberg Human PKG I cDNA was cloned by RT-PCR, using human platelet
et al., 1999; Mellion et al., 1981). Also, cGMP-induced mRNA as the template. The sequence of the PKG I cDNA matches
the published sequence (Sandberg et al., 1989). Cloning of humanplatelet inhibition requires a longer period of preincuba-
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PKG I cDNA was described previously (Browning et al., 2000). PKG incubated with 2 g/ml of rhodamine-labeled phalloidin at 22C
for 30 min. After additional washes, the slides were mounted andI or I in pCDNA3.1/Zeo vector was transfected into 123 cells
using Lipofectamine plus (BRL). Expression of PKG was assessed examined under a Nikon fluorescence microscope.
by immunoblotting with an anti-human PKG I antibody (Calbiochem).
The kinase activity of the expressed enzymes was measured in cell Measurement of cGMP Levels
homogenates using BPDEtide (Calbiochem) as substrate as detailed Washed platelets (3 	 108/ml) in 400 l Tyrode’s buffer were stirred
previously (Colbran et al., 1992). vWF-induced activation of integrin at 37C after addition of control buffer, 1 mg/ml ristocetin alone,
IIb3 was examined by flow cytometric analysis of Oregon green- 15 g/ml vWF, and 1 mg/ml ristocetin, or 100 M glyco-SNAP1
labeled fibrinogen binding to integrin IIb3 as described previously (Calbiochem). The reaction was stopped by addition of 400 l of
(Gu et al., 1999). ice-cold 12% (w/v) trichloroacetic acid. Samples were mixed and
centrifuged at 2000 	 g for 15 min at 4C. The supernatant was
removed and washed four times with 5 volumes of water-saturatedTransfected CHO Cell Adhesion to vWF
diethyl ether and then lyophilized. cGMP levels were measured usingPurified human vWF (50 g/ml in 0.1 M NaHCO3 [pH 8.3]) was added
a cGMP enzyme immunoassay kit from Amersham-Pharmaciato glass microcapillary tubes (inner diameter of 1.17 mm and a length
Biotech.of 7.5 cm) (Warner Instrument Corp) and incubated at 22C for 3 hr.
The vWF-coated microcapillary tubes were then incubated with 5%
nonfat dry milk in phosphate-buffered saline solution (pH 7.4) (PBS) Bleeding Time Analysis in PKG Knockout Mice
to block nonspecific binding. CHO cells expressing human platelet Mice were anesthetized with 2.5% (10 ml/kg) Avertin (100% [w/v]
receptors were resuspended in modified Tyrode’s buffer (pH 7.4) tribromoethyl alcohol in tertiary amyl alcohol) in PBS. Tails were
containing 1 mg/ml of bovine serum albumin (BSA) (Du et al., 1991) amputated 0.5 cm from the tip and immediately immersed in 0.15M
and at a final cell count of 5 	 106/ml. The cell suspension was sodium chloride at 37C. Bleeding time was followed visually and
aspirated through the tube by a syringe pump (Harvard Apparatus, time to cessation was recorded. If bleeding did not naturally stop
Inc.) at a flow rate of 1.42 ml/min (150/s) for 1.2 min. The tube was after 900 s, the wound was pressured to prevent death from hemor-
then washed with modified Tyrode’s buffer for an additional 5 min rhage. The amputated segments of tails were saved for subsequent
at the same flow rates to remove transiently adherent cells. Cell DNA preparation and PCR analysis of genotype as described pre-
interaction with immobilized vWF was observed in real time under viously (Wegener et al., 2002).
a Zeiss inverted microscope equipped with a CCD camera and was
recorded using a video cassette recorder. The number of stably Analysis of cGMP-Induced VASP and ERK
adherent cells on immobilized vWF was counted on images obtained Phosphorylation in Platelets
at 15 randomly selected positions in a vWF-coated tube. Washed human platelets (1	 109/ml) were incubated with 8-bromo-
cGMP for increasing lengths of time at 37C. The platelets were
then solubilized in SDS-PAGE sample buffer, analyzed by SDS-PKG Knockout Mice and Mouse Platelet Preparation
PAGE on 4%–15% gradient gels, and electrotransfered to PVDFThe generation of a PKG null (
) allele by homologous recombina-
membranes. The membranes were immunoblotted with a mono-tion has been described previously (Wegener et al., 2002). Male
clonal antibody, 16C2, specific for the phosphorylated Ser239 site ofand female mice (6–8 weeks) were anesthetized by intraperitoneal
VASP (0.2g/ml) (Smolenski et al., 1998) or a rabbit antibody specificinjection of pentobarbital. Whole blood from homozygous PKG
for the phosphorylated form of ERK (New England Biolabs) as pre-knockout mice or wild-type mice was collected from the inferior
viously described (Li et al., 2001).vena cava using 1/7 volume of ACD (2.5% trisodium citrate, 2%
dextrose, and 1.5% citric acid) as anticoagulant. For each experi-
ment, platelets were pooled from five to six mice of each genotype. Acknowledgments
The platelets were then washed twice with CGS (0.12 M sodium
chloride, 0.0129 M trisodium citrate, 0.03 M D-glucose, [pH 6.5]), We thank Drs. C. Ruan and M.C. Berndt for providing reagents, and
resuspended in Tyrode’s buffer at 2 	 108/ml, and incubated at Drs. M.C. Berndt, P. Newman, and many other colleagues for critical
room temperature for 1 hr before use. reading of various versions of the manuscript. This work was sup-
ported in part by grants from the NHLBI/NIH, HL62350, and
HL68819, and by a Grant-in Aid from AHA. Z.L. is supported byHuman Platelet Preparation and Aggregation Assay
a fellowship award from the American Heart Association MidwestFresh blood from healthy volunteers was anticoagulated with 1/7
Affiliate.volume of ACD. Platelets were washed with CGS, resuspended in
modified Tyrode’s solution, and allowed to incubate at 22C for 1–2
hr as previously described (Du et al., 1991). In experiments using Received: September 12, 2000
platelet-rich plasma (PRP), 1/10 volume of 3.8% trisodium citrate Revised: November 7, 2002
was used as anticoagulant. Platelet aggregation was measured us-
ing a turbidometric platelet aggregometer (Chrono-Log) at 37C. References
vWF-dependent platelet aggregation was induced by addition of
ristocetin or botrocetin to PRP. Washed platelets were used for Arora, R.R., Timoney, M., and Melilli, L. (1999). Acute myocardial
platelet aggregation induced by -thrombin (Enzyme Research Lab- infarction after the use of sildenafil. N. Engl. J. Med. 341, 700.
oratories). To examine the effects of PKG, various concentrations of Aszodi, A., Pfeifer, A., Ahmad, M., Glauner, M., Zhou, X.H., Ny, L.,
the membrane-permeable cGMP analogs 8-bromo-cGMP, 8-pCPT- Andersson, K.E., Kehrel, B., Offermanns, S., and Fassler, R. (1999).
cGMP, or 8-dibutyl-cGMP (Calbiochem), or sildenafil citrate (Pfizer) The vasodilator-stimulated phosphoprotein (VASP) is involved in
were added simultaneously with subthreshold concentrations of cGMP- and cAMP-mediated inhibition of agonist-induced platelet
agonists. The PKG inhibitors KT5823 (2 M) and Rp-pCPT-cGMP aggregation, but is dispensable for smooth muscle function. EMBO
(0.25 mM) (Calbiochem) were preincubated with platelets at 37C J. 18, 37–48.
for 5 min before addition of agonists.
Azula, F.J., Alzola, E.S., Conde, M., Trueba, M., Macarulla, J.M., and
Marino, A. (1996). Thrombin-stimulated phospholipase C activity is
Platelet Spreading on vWF
inhibited without visible delay by a rapid increase in the cyclic GMP
Washed mouse or human platelets were allowed to adhere and
levels induced by sodium nitroprusside. Mol. Pharmacol. 50,
spread on 20 g/ml vWF-coated glass chamber slides (Nunc) at
367–379.
37C for 1 hr in the presence of a low concentration of the vWF
Browning, D.D., McShane, M.P., Marty, C., and Ye, R.D. (2000). Nitricmodulator, botrocetin (0.5 g/ml), which enhances vWF-GPIb-IX
oxide activation of p38 mitogen-activated protein kinase in 293Tinteraction. After three washes, platelets were fixed by adding 4%
fibroblasts requires cGMP-dependent protein kinase. J. Biol. Chem.paraformaldehyde in PBS, permeabilized by adding 0.1 M Tris, 0.01
275, 2811–2816.M EGTA, 0.15 M NaCl, 5 mM MgCl2 [pH 7.4], containing 0.1% Triton
X-100, 0.5 mM leupeptin, 1 mM PMSF, and 0.1 mM E64, and then Canobbio, I., Bertoni, A., Lova, P., Paganini, S., Hirsch, E., Sinigaglia,
Platelet Activation Via Protein Kinase G
85
F., Balduini, C., and Torti, M. (2001). Platelet activation by von Wille- Increased adhesion and aggregation of platelets lacking cyclic gua-
nosine 3,5-monophosphate kinase I. J. Exp. Med. 189, 1255–1264.brand factor requires coordinated signaling through thromboxane
A2 and FCIIA receptor. J. Biol. Chem. 276, 26022–26029. Maurice, D.H., and Haslam, R.J. (1990). Molecular basis of the syner-
Colbran, J.L., Francis, S.H., Leach, A.B., Thomas, M.K., Jiang, H., gistic inhibition of platelet function by nitrovasodilators and activa-
McAllister, L.M., and Corbin, J.D. (1992). A phenylalanine in peptide tors of adenylate cyclase: inhibition of cyclic AMP breakdown by
substrates provides for selectivity between cGMP- and cAMP- cyclic GMP. Mol. Pharmacol. 37, 671–681.
dependent protein kinases. J. Biol. Chem. 267, 9589–9594. Mellion, B.T., Ignarro, L.J., Ohlstein, E.H., Pontecorvo, E.G., Hyman,
Corbin, J.D., and Francis, S.H. (1999). Cyclic GMP phosphodiester- A.L., and Kadowitz, P.J. (1981). Evidence for the inhibitory role of
ase-5: target of sildenafil. J. Biol. Chem. 274, 13729–13732. guanosine 3, 5-monophosphate in ADP-induced human platelet
aggregation in the presence of nitric oxide and related vasodilators.Coughlin, S.R. (2000). Thrombin signalling and protease-activated
Blood 57, 946–955.receptors. Nature 407, 258–264.
Mitka, M. (2000). Some men who take Viagra die–why? Jama 283,De Marco, L., Girolami, A., Russell, S., and Ruggeri, Z.M. (1985).
590, 593.Interaction of asialo von Willebrand factor with glycoprotein Ib in-
duces fibrinogen binding to the glycoprotein IIb/IIIa complex and Pfeifer, A., Klatt, P., Massberg, S., Ny, L., Sausbier, M., Hirneiss, C.,
mediates platelet aggregation. J. Clin. Invest. 75, 1198–1203. Wang, G.X., Korth, M., Aszodi, A., Andersson, K.E., et al. (1998).
Defective smooth muscle regulation in cGMP kinase I-deficientDu, X., and Ginsberg, M.H. (1999). Signaling and platelet adhesion.
mice. EMBO J. 17, 3045–3051.Advances in Molecular and Cell Biology 28, 269–301.
Porter, A., Mager, A., Birnbaum, Y., Strasberg, B., Sclarovsky, S., andDu, X., Plow, E.F., Frelinger, A.L.I., O’Toole, T.E., Loftus, J.C., and
Rechavia, E. (1999). Acute myocardial infarction following sildenafilGinsberg, M.H. (1991). Ligands “activate” integrin IIb3 (platelet
citrate (Viagra) intake in a nitrate-free patient. Clin. Cardiol. 22,GPIIb-IIIa). Cell 65, 409–416.
762–763.Feenstra, J., van Drie-Pierik, R.J., Lacle, C.F., and Stricker, B.H.
Ramakrishnan, V., DeGuzman, F., Bao, M., Hall, S.W., Leung, L.L.,(1998). Acute myocardial infarction associated with sildenafil. Lancet
and Phillips, D.R. (2001). A thrombin receptor function for platelet352, 957–958.
glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc.Freedman, J.E., Loscalzo, J., Barnard, M.R., Alpert, C., Keaney, J.F.,
Natl. Acad. Sci. USA 98, 1823–1828.and Michelson, A.D. (1997). Nitric oxide released from activated
Ruan, C.G., Du, X.P., Xi, X.D., Castaldi, P.A., and Berndt, M.C. (1987).platelets inhibits platelet recruitment. J. Clin. Invest. 100, 350–356.
A murine antiglycoprotein Ib complex monoclonal antibody, SZ 2,Furchgott, R.F., and Vanhoutte, P.M. (1989). Endothelium-derived
inhibits platelet aggregation induced by both ristocetin and collagen.relaxing and contracting factors. FASEB J. 3, 2007–2018.
Blood 69, 570–577.
Ginsberg, M.H., Du, X., and Plow, E.F. (1992). Inside-out integrin
Sakariassen, K.S., Bolhuis, P.A., and Sixma, J.J. (1979). Humansignalling. Curr. Opin. Cell Biol. 4, 766–771.
blood platelet adhesion to artery subendothelium is mediated by
Gralnick, H.R., Williams, S.B., and Coller, B.S. (1985). Asialo von factor VIII-von Willebrand factor bound to the subendothelium. Na-
Willebrand factor interactions with platelets. Interdependence of ture 279, 636–638.
glycoproteins Ib and IIb/IIIa for binding and aggregation. J. Clin.
Sandberg, M., Natarajan, V., Ronander, I., Kalderon, D., Walter, U.,Invest. 75, 19–25.
Lohmann, S.M., and Jahnsen, T. (1989). Molecular cloning and pre-
Greco, N.J., Tandon, N.N., Jones, G.D., Kornhauser, R., Jackson, dicted full-length amino acid sequence of the type I beta isozyme
B., Yamamoto, N., Tanoue, K., and Jamieson, G.A. (1996). Contribu- of cGMP-dependent protein kinase from human placenta. Tissue
tions of glycoprotein Ib and the seven transmembrane domain re- distribution and developmental changes in rat. FEBS Lett. 255,
ceptor to increases in platelet cytoplasmic [Ca2] induced by alpha- 321–329.
thrombin. Biochemistry 35, 906–914.
Savage, B., Shattil, S.J., and Ruggeri, Z.M. (1992). Modulation of
Gu, M., Xi, X., Englund, G.D., Berndt, M.C., and Du, X. (1999). Analysis platelet function through adhesion receptors. A dual role for glyco-
of the roles of 14-3-3 in the platelet glycoprotein Ib-IX-mediated protein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and
activation of integrin IIb3 using a reconstituted mammalian cell glycoprotein Ib-von Willebrand factor. J. Biol. Chem. 267, 11300–
expression model. J. Cell Biol. 147, 1085–1096. 11306.
Halbrugge, M., Friedrich, C., Eigenthaler, M., Schanzenbacher, P., Savage, B., Saldivar, E., and Ruggeri, Z.M. (1996). Initiation of plate-
and Walter, U. (1990). Stoichiometric and reversible phosphorylation let adhesion by arrest onto fibrinogen or translocation on von Wille-
of a 46-kDa protein in human platelets in response to cGMP- and brand factor. Cell 84, 289–297.
cAMP-elevating vasodilators. J. Biol. Chem. 265, 3088–3093.
Shattil, S.J., Kashiwagi, H., and Pampori, N. (1998). Integrin signal-
Haslam, R.J., Dickinson, N.T., and Jang, E.K. (1999). Cyclic nucleo-
ing: the platelet paradigm. Blood 91, 2645–2657.
tides and phosphodiesterases in platelets. Thromb. Haemost. 82,
Smolenski, A., Bachmann, C., Reinhard, K., Honig-Liedl, P., Jarchau,412–423.
T., Hoschuetzky, H., and Walter, U. (1998). Analysis and regulation
Hauser, W., Knobeloch, K.P., Eigenthaler, M., Gambaryan, S., Krenn,
of vasodilator-stimulated phosphoprotein serine 239 phosphoryla-
V., Geiger, J., Glazova, M., Rohde, E., Horak, I., Walter, U., and
tion in vitro and in intact cells using a phosphospecific monoclonal
Zimmer, M. (1999). Megakaryocyte hyperplasia and enhanced ago-
antibody. J. Biol. Chem. 273, 20029–20035.
nist-induced platelet activation in vasodilator-stimulated phospho-
Sullam, P.M., Hyun, W.C., Szollosi, J., Dong, J., Foss, W.M., andprotein knockout mice. Proc. Natl. Acad. Sci. USA 96, 8120–8125.
Lopez, J.A. (1998). Physical proximity and functional interplay of the
Hood, J., and Granger, H.J. (1998). Protein kinase G mediates vascu-
glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on
lar endothelial growth factor-induced Raf-1 activation and prolifera-
the platelet plasma membrane. J. Biol. Chem. 273, 5331–5336.
tion in human endothelial cells. J. Biol. Chem. 273, 23504–23508.
Wallis, R.M., Corbin, J.D., Francis, S.H., and Ellis, P. (1999). Tissue
Jamieson, G.A., and Okumura, T. (1978). Reduced thrombin binding
distribution of phosphodiesterase families and the effects of sil-
and aggregation in Bernard-Soulier platelet. J. Clin. Invest. 61,
denafil on tissue cyclic nucleotides, platelet function, and the con-
861–864.
tractile responses of trabeculae carneae and aortic rings in vitro.
Li, Z., Xi, X., and Du, X. (2001). A mitogen-activated protein kinase- Am. J. Cardiol. 83, 3C–12C.
dependent signaling pathway in the activation of platelet integrin
Ward, C.M., Andrews, R.K., Smith, A.I., and Berndt, M.C. (1996).
IIb3. J. Biol. Chem. 276, 42226–42232.
Mocarhagin, a novel cobra venom metalloproteinase, cleaves the
Lopez, J.A., Andrews, R.K., Afshar-Kharghan, V., and Berndt, M.C. platelet von Willebrand factor receptor glycoprotein Ibalpha. Identifi-
(1998). Bernard-Soulier syndrome. Blood 91, 4397–4418. cation of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282
of glycoprotein Ibalpha as a binding site for von Willebrand factorMassberg, S., Sausbier, M., Klatt, P., Bauer, M., Pfeifer, A., Siess,
W., Fassler, R., Ruth, P., Krombach, F., and Hofmann, F. (1999). and alpha-thrombin. Biochemistry 35, 4929–4938.
Cell
86
Wegener, J.W., Nawrath, H., Wolfsgruber, W., Kuhbandner, S., Wer-
ner, C., Hofmann, F., and Feil, R. (2002). cGMP-dependent protein
kinase I mediates the negative inotropic effect of cGMP in the murine
myocardium. Circ. Res. 90, 18–20.
Weiss, H.J., Turitto, V.T., and Baumgartner, H.R. (1978). Effect of
shear rate on platelet interaction with subendothelium in citrated
and native blood. I. Shear rate dependent decrease of adhesion in
von Willebrand’s disease and the Bernard-Soulier syndrome. J. Lab.
Clin. Med. 92, 750–764.
Wu, Y., Suzuki-Inoue, K., Satoh, K., Asazuma, N., Yatomi, Y., Berndt,
M.C., and Ozaki, Y. (2001). Role of Fc receptor gamma-chain in
platelet glycoprotein Ib-mediated signaling. Blood 97, 3836–3845.
Yamamoto, N., Kitagawa, H., Tanoue, K., and Yamazaki, H. (1985).
Monoclonal antibody to glycoprotein Ib inhibits both thrombin- and
ristocetin-induced platelet aggregations. Thromb. Res. 39, 751–759.
Yan, B., and Smith, J.W. (2000). A redox site involved in integrin
activation. J. Biol. Chem. 275, 39964–39972.
